CJC-1295 NO DAC Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks on, 4 weeks off; extended cycles run 12 to 16 weeks with a proportionally longer break
• Frequency: Once daily is the standard pattern; twice daily is used for more advanced protocols
• Common delivery routes: Subcutaneous injection
• Key timing notes: Fasted state is required; bedtime dosing is the primary window, timed to align with the body's natural nocturnal GH pulse

Who This Protocol Is For

CJC-1295 NO DAC draws users who are looking for consistent, compounding improvement rather than rapid, dramatic change. The goals most commonly associated with it include gradual body recomposition, faster recovery from training, improved sleep quality, and longer-term connective tissue and skin support. It is not a compound people reach for when they want a short-term spike.

Experience level matters in how the protocol is structured. Someone earlier in their peptide journey typically runs it solo, keeping the protocol simple while learning how their body responds to GHRH stimulation. More experienced users commonly pair it with Ipamorelin to engage two complementary pathways simultaneously, producing a larger and more physiologically complete GH pulse than either compound delivers alone.

Delivery route is subcutaneous injection only. There is no oral or nasal alternative with meaningful efficacy for this compound. The protocol requires fasted timing, consistent daily discipline, and comfort with subcutaneous administration. Users already familiar with injecting other peptides find the logistics straightforward; those newer to injections will want to factor in the learning curve.

How Is a CJC-1295 NO DAC Cycle Structured?

A CJC-1295 NO DAC cycle is built around one core pharmacological fact: this compound has a short half-life, with the active GH stimulus window lasting roughly thirty minutes after injection. That makes it fundamentally different from CJC-1295 WITH DAC, which binds to albumin in the blood and stays active for days. The NO DAC version stimulates a sharp, pulsatile GH release and then clears, mimicking the way the body naturally releases growth hormone (GHRH, or growth hormone releasing hormone, is the signal that drives that release) rather than sustaining a continuous stimulus. That pulsatile pattern is why the protocol looks the way it does.

A standard cycle runs eight to twelve weeks, followed by a four-week break. Extended cycles of twelve to sixteen weeks are used, primarily for anti-aging and longevity goals, with proportionally longer off periods. The cycle does not follow a traditional loading-then-maintenance split where the dose jumps between phases. Instead, the dose starts conservatively, builds upward through a gradual titration over the first several weeks, and then holds steady at a target level for the bulk of the cycle. The full detail of how that titration unfolds lives in the Loading and Maintenance Phases section below.

The off period is not optional padding. The pituitary's GHRH receptors can desensitize with prolonged continuous stimulation, and effectiveness typically drops noticeably after four to five months of uninterrupted use. The break allows those receptors to reset, lets GH and IGF-1 (insulin-like growth factor 1, a protein the liver releases in response to elevated growth hormone) normalize, and means the next cycle starts fresh.

How Your Dose Is Determined

What moves a CJC-1295 NO DAC dose:

• Your goal: Body composition, recovery, and performance optimization goals tend to sit toward the lower end of the range, where the protocol is sustainable across a full cycle. The higher end shows up mostly in practitioner protocols for more aggressive body composition goals, particularly when the compound is stacked with Ipamorelin. Anti-aging and connective tissue support goals tend to stay in the moderate band, which sits at roughly the same level as body-composition maintenance goals rather than the higher end associated with aggressive recomposition, because consistent stimulation over a longer cycle matters more than peak intensity.
• Experience level: A first-cycle user starts at the conservative end and builds gradually, spending the first one to two weeks at the starting point before titrating upward in small steps. Someone with prior GHRH peptide experience who knows their response may move through the titration period more quickly. The principle is consistent: start low, observe, and increase only when the current level is clearly well-tolerated.
• Delivery route and dosing pattern: CJC-1295 NO DAC is subcutaneous only. Whether the daily dose is taken once at bedtime or split across two daily administrations shifts how the total daily amount is distributed. A twice-daily pattern, typically adding a midday or post-workout administration to the primary bedtime dose, is a timing strategy tied to the compound's short half-life rather than a blanket higher-is-better approach.
• Individual response: Two people running the same goal at the same experience level can land in meaningfully different places. Sleep disruption, fluid retention, appetite changes, or a wired feeling after injection are all signals that the dose needs to come down, not up. IGF-1 response also varies enough across individuals that some users see strong GH axis activation at the lower end while others show minimal response at the same level.

No single dose fits everyone running this protocol. The interaction between goal, experience, individual response, and whether the compound is stacked is what determines where someone actually lands, which is exactly what the app personalizes.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type, whether you are running CJC-1295 NO DAC solo or stacking with Ipamorelin, and whether you plan once or twice daily dosing and builds your CJC-1295 NO DAC protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take CJC-1295 NO DAC?

The standard pattern is once daily, taken before bed in a fasted state. That frequency is not arbitrary. CJC-1295 NO DAC has a half-life of roughly thirty minutes, so the GH pulse it triggers peaks within fifteen to thirty minutes of injection and clears within about two hours. The bedtime window is prioritized because the body's largest natural GH pulse occurs during deep sleep, and injecting immediately before sleep, while fasted, allows the compound to amplify that existing nocturnal pulse rather than triggering a daytime spike that works against normal cortisol and insulin rhythms.

The fasted state requirement is a hard timing constraint. Elevated insulin from food blunts GH release because insulin and GH are antagonistic signals. The standard protocol calls for fasting ninety to one hundred and twenty minutes before injection, then waiting thirty to sixty minutes after injection before eating. Dosing outside this window meaningfully reduces the GH pulse the compound produces.

A twice-daily pattern is used for more advanced protocols, typically adding a midday or post-workout administration to the primary bedtime dose, targeting a second daily GH pulse during the window when training-induced GH sensitivity is elevated. Both administrations follow the same fasted requirement. Some protocols also use a five-days-on, two-days-off weekly schedule, with the weekend break intended to further reduce any receptor desensitization risk over the course of the cycle.

Consistency matters more than clock-time precision. Hitting the bedtime window reliably in a fasted state throughout the cycle produces better results than a theoretically optimal schedule that gets missed frequently.

Loading and Maintenance Phases

CJC-1295 NO DAC does not use a traditional loading phase where a higher initial dose front-loads the compound and then drops to a lower maintenance level. The structure works differently: the dose starts conservatively and builds upward through a titration period, then holds steady at a target level through the rest of the cycle. Think of it less as a loading-then-maintenance jump and more as a ramp that flattens out.

The titration period typically occupies the first four to six weeks. The first one to two weeks establish the starting point at the lower end of the range, giving the body time to adjust to GHRH stimulation. Every one to two weeks after that, if the current level is well-tolerated with no significant side effects, the dose steps up by a small increment. By weeks five through six in most protocols, the dose has reached its target level.

Once the target is reached, that dose holds steady through the maintenance period, running from roughly week five or six through the end of the cycle. The goal during maintenance is steady, consistent stimulation at the established level, timed reliably each day in a fasted state.

One point that frequently causes confusion: the titration and maintenance periods share the same route, timing, and frequency. What changes during titration is only the dose level itself. Once maintenance begins, that level locks in for the remainder of the cycle.

Off-Cycle Considerations

Off-cycle periods are a functional part of the CJC-1295 NO DAC protocol. The pituitary's GHRH receptors can downregulate with prolonged continuous stimulation, and most protocols show meaningful diminishing returns beginning somewhere after four to five months of continuous use. The off period gives those receptors time to reset and allows GH and IGF-1 levels to normalize before the next cycle begins.

The standard off period for an eight-to-twelve-week cycle is four weeks. Extended cycles of twelve to sixteen weeks typically use an off period of six to eight weeks. Because the NO DAC version has a short half-life, GH levels return to baseline relatively quickly after the last injection, typically within one to two weeks. IGF-1 takes somewhat longer to normalize, usually three to four weeks. The four-week minimum off period is designed to cover that full IGF-1 normalization window.

Some users who run CJC-1295 NO DAC for anti-aging or longevity goals structure their year into roughly three cycles, with a month between each, creating a sustainable annual rhythm that avoids the receptor fatigue of continuous use. Whether to cycle in that pattern or run fewer annual cycles depends on the individual's goals and how their response has tracked over time.

What to Expect Week by Week

• Week 1 to 2: Sleep is the first thing most users notice. Reports of deeper, more restorative sleep and a reduction in recovery time after training are the most consistently noted early effects. A mild head flush or tingling sensation in the minutes immediately after injection is common and typically resolves within ten minutes. Meaningful training performance changes are rarely apparent this early.
• Week 3 to 4: Training begins to feel different. Weights that previously felt heavy feel more manageable, and the perceived effort of a given workload decreases. Users commonly describe this as a "pop" in their training, with strength progressing consistently. Early fat loss may begin to appear, typically subtle rather than dramatic, alongside initial improvements in how muscles look and feel.
• Week 5 to 8: Body composition changes become more visually apparent. Fat loss continues at a gradual pace, and muscles take on a fuller, more hydrated appearance that users consistently describe as distinct from the water weight associated with other compounds. Training capacity continues to improve, and tolerance for higher training volume without accumulating fatigue becomes noticeable.
• Beyond 8 weeks: Connective tissue support, including tendons, ligaments, and joints, is commonly reported after extended cycles. Skin changes, including improved elasticity and texture, appear in the two-to-three-month range for many users. These systemic benefits build more slowly than the early sleep and performance improvements but are consistently reported across longer cycles.

These are commonly reported ranges drawn from real-world protocol data, not guarantees. Individual results vary by timing discipline, whether a stack is used, and individual GH axis response. Many users who run a well-structured cycle report an arc that looks something like this: consistent sleep improvement from the first weeks, steady training progress building through the middle of the cycle, and a clear if gradual body composition shift by the final weeks, with connective tissue and skin benefits continuing to develop beyond the eight-week mark. The compound rewards patience and consistency more than any other single variable.

Common Protocol Mistakes

Confusing the DAC and NO DAC versions. This is the most consequential mistake in the CJC-1295 space. The two compounds have fundamentally different half-lives and completely different dosing requirements. Applying a DAC dosing schedule to the NO DAC version either produces a poorly-timed GH stimulus or wastes the compound. Before starting, confirm explicitly which variant you have. Products labeled simply "CJC-1295" without further specification are often the NO DAC version, but that is not guaranteed.

Dosing outside a fasted state. Food raises insulin, and elevated insulin blunts GH release. This is a mechanistic interaction, not a minor optimization point. The fasting window before and after injection is a hard protocol requirement, and skipping it meaningfully reduces the GH pulse the compound produces.

Missing the bedtime window consistently. The nocturnal GH pulse is the largest the body produces in a twenty-four-hour period. Bedtime dosing is specifically timed to amplify it. Dosing at random times without regard for fasted state or the natural GH rhythm substantially reduces the protocol's efficacy.

Running continuously without an off period. Receptor desensitization is real. Effectiveness typically declines noticeably after four to five months of continuous use, and the minimum four-week break exists to cover the full IGF-1 normalization window and allow GHRH receptors to reset.

Increasing the dose when experiencing poor sleep or a wired feeling. These are signals that the current level is too high. The correct response is to reduce the dose. A wired post-injection feeling at bedtime directly undermines the sleep benefit that makes CJC-1295 NO DAC worth running, and users who push through by adding more dose commonly see sleep quality deteriorate significantly.

Sourcing from unverified suppliers. Product purity, quality, and even variant identity are not guaranteed from unverified sources. Third-party tested product through a verifiable supply chain matters here, and the difference between a verified and unverified source is not a minor detail.

CJC-1295 NO DAC is not FDA-approved for human use. Competitive athletes subject to testing should also know it is prohibited by the World Anti-Doping Agency, and use can result in disqualification.

Frequently Asked Questions

How long is a typical CJC-1295 NO DAC cycle?

The most common cycle runs eight to twelve weeks, followed by a four-week off period. Extended cycles of twelve to sixteen weeks are used by some, particularly for anti-aging and longevity goals, and pair with a proportionally longer break of six to eight weeks. Individual cycle length within those ranges depends on goals, response, and how the protocol is structured overall.

How often do you take CJC-1295 NO DAC?

Once daily is the standard pattern, typically timed before bed in a fasted state to align with the body's natural nocturnal GH pulse. A twice-daily pattern is used by some more advanced users, adding a midday or post-workout administration to the primary bedtime dose. Both administrations require the same fasted window, reflecting the compound's short half-life and the need to keep insulin low for each GH pulse.

Does CJC-1295 NO DAC need a loading phase?

Not in the traditional sense. Rather than a high-dose front-load followed by a reduced maintenance dose, CJC-1295 NO DAC is run through a gradual titration: starting conservatively in the first one to two weeks and stepping up in small increments every one to two weeks until the target level is reached, at which point the dose holds steady for the rest of the cycle.

Do you need to cycle off CJC-1295 NO DAC?

Yes. Continuous use without a break leads to GHRH receptor desensitization at the pituitary, and most users see a measurable reduction in effectiveness after four to five months of uninterrupted use. The standard four-week break after an eight-to-twelve-week cycle allows GH levels to return to baseline and IGF-1 to normalize fully before the next cycle begins.

What is the difference between CJC-1295 NO DAC and CJC-1295 WITH DAC?

The core difference is half-life and dosing frequency. The NO DAC version clears the system within roughly two hours of injection, producing a sharp, pulsatile GH release that mimics the body's natural rhythm. The WITH DAC version binds to albumin and remains active for five to eight days, requiring only one to two injections per week but producing a sustained rather than pulsatile GH profile. These are not interchangeable compounds, and applying one version's schedule to the other is one of the most common mistakes in this space.

Can CJC-1295 NO DAC be stacked with Ipamorelin?

Yes, and it is the most common approach for this compound. CJC-1295 NO DAC acts on the GHRH receptor to stimulate GH release, while Ipamorelin acts on the ghrelin receptor through a separate pathway. Combining them produces a synergistic, larger GH pulse than either compound generates alone, and most protocols run the two together in the same subcutaneous injection before bed.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for CJC-1295 NO DAC in one place.